Allogene Therapeutics
Lillian Smith, currently serving as Vice President and Corporate Counsel at Allogene Therapeutics since August 2018, has a strong background in legal counsel within the biotechnology and healthcare sectors. Prior roles include Corporate Counsel at Kite Pharma, Legal Counsel at Children's Hospital Los Angeles, and Director of Strategic Initiatives & Legal Liaison at UCLA's Office of the Vice Chancellor of Research. Lillian's experience also encompasses directing industry-sponsored research at UCLA and practicing as an attorney at Kirkland & Ellis LLP and Rothwell, Figg, Ernst & Manbeck. Educational qualifications include a J.D. from the University of New Hampshire - Franklin Pierce Law Center, where Lillian was a Franklin Pierce Scholar, and a B.A. in Biology from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.